Invivyd Logo
About
Mission
Leadership Team
Board of Directors
Partnerships
Platform
Overview
Scientific Publications
Pipeline
Overview
COVID-19
Influenza
Clinical Trials
Product
Investors & Media
Overview
Press Releases
Events & Presentations
Analyst Coverage
Stock Information
Financials & Filings
Corporate Governance
Scientific Publications
Resources
Careers
Our Culture & Values
Open Positions
Contact Us
Boldl
y
HARNESSING A NOVEL APPROACH
Scientific publications
<
In vitro
neutralisation of pemivibart (VYD222) against Omicron sublineages.
West et al.
ECCMID
. 2024.
Preliminary safety results from a phase 1 first in human study of VYD222: an extended half-life monoclonal antibody (mAb) in development for COVID-19 prevention.
Mahoney et al.
IDWeek
. 2023.
Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase 2/3 randomized, double-blind, placebo-controlled trial (EVADE).
Ison et al.
Open Forum Infectious Diseases.
2023.
Efficacy and safety of adintrevimab (ADG20) for the treatment of high-risk ambulatory patients with mild or moderate COVID-19: results from a phase 2/3, randomized, placebo-controlled trial (STAMP) conducted during Delta predominance and early emergence of Omicron.
Ison et al.
Open Forum Infectious Diseases.
2023.
Assessment of effect of adintrevimab on COVID-19 vaccine response.
Tosh et al.
ISIRV-AVG.
2023.
NVD200 potently neutralizes Omicron and its sublineages.
West et al.
ECCMID.
2023.
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.
Schmidt et al.
Science Translational Medicine.
2023.
ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants.
Kaku et al.
ECCMID.
2022.
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.
Rubino et al.
ECCMID.
2022.
Results from the phase 2/3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of adintrevimab (ADG20) in the treatment of ambulatory participants with mild or moderate COVID-19 (STAMP).
Popejoy et al.
ASM Microbe.
2022.
Broad and potent in vitro neutralization of SARS-CoV-2 variants by ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19.
Kaku et al.
ISIRV-WHO.
2021.
Evaluating the safety, tolerability, and pharmacokinetics of ADG20, a half-life–extended monoclonal antibody (mAb) in development for the prevention and treatment of COVID-19: a preliminary analysis of a randomized phase 1 study.
Schmidt et al.
ISIRV-WHO.
2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model that a priori predicts pharmacokinetics of ADG20: an extended half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.
Van Wart et al.
ID Week.
2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support dose selection of ADG20: an extended half-life monoclonal antibody being developed for the treatment of coronavirus disease (COVID-19).
Tarbell et al.
ID Week.
2021.
More
Older publications
Use of a whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support ADG20 dose selection for the prevention of coronavirus disease (COVID-19).
Van Wart et al.
ID Week.
2021.
Preliminary results from a phase 1 single ascending-dose study assessing safety, pharmacokinetic profile, and serum viral neutralizing antibody titers of ADG20: an extended half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.
Paguntalan et al.
ID Week.
2021.
The ADG20 human monoclonal antibody binds with high affinity and neutralises a wide range of SARS-CoV-2 variants and zoonotic Sarbecoviruses.
Kaku et al.
ECCMID.
2021.
Prophylactic administration of the monoclonal antibody ADG20 provides potent protection against SARS-CoV-2 in rodent and non-human primate models of COVID-19.
Narayan et al.
ECCMID.
2021.
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
Rappazzo et al.
Science.
2021.
An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19.
Rappazzo et al.
bioRxiv.
2020.
Broad neutralization of SARS-related antibodies by human monoclonal antibodies.
Wec et al.
Science.
2020.
The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.